CRBU - Caribou Biosciences Inc

CRBU - Caribou Biosciences Inc

https://cariboubio.com

Recent News

Powered by Alpha Vantage

Caribou Biosciences ( CRBU ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 4 months ago • score: 0.35

Caribou Biosciences (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Caribou Biosciences, Inc. ( CRBU ) Reports Q1 Loss, Misses Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.00

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 0% and 5.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$3.00

52W Low

$0.66

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.55

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-36.94

EV/Revenue (<3 favorable)

1.76

P/S (TTM) (<3 favorable)

19.09

P/B (<3 favorable)

1.05

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

9.82%

Institutions (25–75% balanced)

42.40%

Shares Outstanding

93,123,000

Float

84,058,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

9,121,000

Gross Profit (TTM)

-119,863,000

EPS (TTM)

-1.78

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-13.28%

ROE (TTM) (>15% strong)

-0.69%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.23

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—